Article

COVID-19: Sun Pharmaceuticals business update

Author(s):

Mark Hagler

Mark Hagler, senior vice president, head of Ophthalmics, Oncology and LTC, at Sun Pharmaceuticals, shares a business update on how the company has responded and continued operations during the coronavirus pandemic.
 

 

 

See more coronavirus coverage here

Related Videos
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
Related Content
Cencora to acquire Retina Consultants of America for upwards of $5.1 Billion
November 13th 2024

Cencora to acquire Retina Consultants of America for upwards of $5.1 Billion

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

HuidaGene Therapeutics' IND application for HG202 for the treatment of nAMD cleared by FDA
November 12th 2024

HuidaGene Therapeutics' IND application for HG202 for the treatment of nAMD cleared by FDA

EyePod podcast: Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
November 1st 2024

Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)

Study explores the true costs of treating pediatric cataracts
November 12th 2024

Study explores the true costs of treating pediatric cataracts

Noninvasive choroidal vessel analysis using deep learning: A novel approach to OCT angiography
November 11th 2024

Noninvasive choroidal vessel analysis using deep learning: A novel approach to OCT angiography

© 2024 MJH Life Sciences

All rights reserved.